Rebus (RBSH) 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 05, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Registrant Name	Inspyr Therapeutics, Inc.
Entity Central Index Key	1,421,204
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NSPX
Entity Common Stock, Shares Outstanding		41,762,356

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 926	$ 2,465
Prepaid expenses	68	114
Total current assets	994	2,579
Office equipment, net of accumulated depreciation of $29 and $27	10	12
Intangible assets, net of accumulated amortization of $136 and $128	76	84
Other assets	3	3
Total assets	1,083	2,678
Current liabilities:
Accounts payable	828	977
Accrued expenses	2,683	2,432
Derivative liability	422	1,177
Total current liabilities	3,933	4,586
Total liabilities	3,933	4,586
Commitments and contingencies
Stockholders’ deficit:
Convertible preferred stock, par value $.0001 per share; 30,000,000 shares authorized, 1,853 issued and outstanding, respectively	0	0
Common stock, par value $0.0001 per share; 150,000,000 shares authorized, 41,762,356 shares issued and outstanding, respectively	4	4
Additional paid-in capital	43,391	43,353
Accumulated deficit	(46,245)	(45,265)
Total stockholders’ deficit	(2,850)	(1,908)
Total liabilities and stockholders’ deficit	$ 1,083	$ 2,678

CONDENSED BALANCE SHEETS _Paren

CONDENSED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Office equipment, accumulated depreciation (in dollars)	$ 29	$ 27
Intangible assets, accumulated amortization (in dollars)	$ 136	$ 128
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	30,000,000	30,000,000
Preferred stock, shares issued	1,853	1,853
Preferred stock, shares outstanding	1,853	1,853
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	41,762,356	41,762,356
Common stock, shares outstanding	41,762,356	41,762,356

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Research and development	$ 323	$ 610	$ 646	$ 1,425
General and administrative	384	921	1,091	1,949
Total operating expenses	707	1,531	1,737	3,374
Loss from operations	(707)	(1,531)	(1,737)	(3,374)
Gain on change in fair value of derivative liability	217	0	755	0
Interest income (expense), net	0	(1)	2	(1)
Loss before provision for income taxes	(490)	(1,532)	(980)	(3,375)
Provision for income taxes	0	0	0	0
Net loss	$ (490)	$ (1,532)	$ (980)	$ (3,375)
Net loss per common share, basic and diluted	$ (0.01)	$ (0.05)	$ (0.02)	$ (0.1)
Weighted average shares outstanding	41,762,356	33,548,366	41,762,356	33,425,058

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - 6 months ended Jun. 30, 2016 - USD ($) $ in Thousands	Total	Convertible Preferred Stock [Member]	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Dec. 31, 2015	$ (1,908)	$ 0	$ 4	$ 43,353	$ (45,265)
Balance (in shares) at Dec. 31, 2015		1,853	41,762,356
Stock-based compensation	38	$ 0	$ 0	38	0
Net loss	(980)	0	0	0	(980)
Balance at Jun. 30, 2016	$ (2,850)	$ 0	$ 4	$ 43,391	$ (46,245)
Balance (in shares) at Jun. 30, 2016		1,853	41,762,356

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (980)	$ (3,375)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	11	10
Stock-based compensation	38	165
Gain on change in fair value of derivative liability	(755)	0
Decrease (increase) in operating assets:
Prepaid expenses	46	116
Increase (decrease) in operating liabilities:
Accounts payable and accrued expenses	101	606
Cash used in operating activities	(1,539)	(2,478)
Cash flows from investing activities:
Acquisition of office equipment	0	(4)
Cash used in investing activities	0	(4)
Cash flows from financing activities:
Proceeds from exercise of warrants	0	287
Cash provided by financing activities	0	287
Net decrease in cash	(1,539)	(2,195)
Cash and cash equivalents, beginning of period	2,465	2,316
Cash and cash equivalents, end of period	$ 926	$ 121

BACKGROUND

BACKGROUND	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	NOTE 1 – BACKGROUND GenSpera, Inc. (“we”, “us”, “our company”, “our”, “GenSpera” or the “Company”) was formed under the laws of the State of Delaware in November 2003, and has its principal office in San Antonio, Texas. We are an early-stage, pre-revenue, pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including brain, liver, prostate and other cancers. We plan to develop a series of therapies based on our target-activated prodrug technology platform. Effective August 1, 2016, pursuant to a certificate of amendment to our amended and restated certificate of incorporation, we changed our corporate name from GenSpera, Inc. to Inspyr Therapeutics, Inc. Effective August 1, 2016, our common stock ceased trading under the symbol “GNSZ” and began trading under the symbol NSPX on August 2, 2016. Our primary focus at the present time is the clinical development of our lead compound, mipsagargin (formerly referred to as G-202), a novel therapeutic agent with a unique mechanism of action. We have completed a Phase 1a/1b dose escalation, safety, tolerability and dose refinement study of mipsagargin, in which we treated a total of 44 patients, including two patients with hepatocellular carcinoma (HCC), or liver cancer, who experienced prolonged stabilization of disease of up to eleven months after initiation of treatment. In addition, we have completed an open label single arm Phase II clinical trial of mipsagargin in subjects with liver cancer, in which twenty-five patients were treated. In May 2015, we received a final clinical study report, and consider the results of the study to be positive, with 63% of treated patients having stable disease at two (2) months and a median time to progression of 4.5 months. In the first quarter of 2014, we entered into a collaborative arrangement to conduct a Phase II clinical trial entitled, “G-202-004:An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients with Recurrent or Progressive Glioblastoma.” In May 2015, we announced that based on preliminary data obtained in the first stage of the trial, we were expanding the trial to a potential 34 patients. In September 2015, we announced interim data from 11 patients with glioblastoma which demonstrated potential clinical benefit in a subset of patients with high levels of PSMA expression in the primary tumor. As of July 22, 2016, we have treated twenty-five subjects in the trial. In the second quarter of 2016, we initiated a Phase II clinical pilot study in patients with prostate cancer entitled, “G-202-005: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 Administered in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients with Adenocarcinoma of the Prostate”, via a collaborative agreement with a single site in the U.S., in which one patient has been enrolled as of July 22, 2016. In the second quarter of 2016, we opened enrollment for a Phase II clinical pilot study in patients with clear cell renal cell carcinoma entitled, “G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients with Clear Cell Renal Cell Carcinoma that Expresses PSMA”, via a collaborative agreement with a single site in the U.S. As of July 22, 2016, one patient has been enrolled. While we believe that the data from the completed trials appear promising, the outcome of our ongoing or future trials may ultimately be unsuccessful.

MANAGEMENT'S PLANS TO CONTINUE

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN	6 Months Ended
	Jun. 30, 2016
Management Plans to Continue as Going Concern [Abstract]
Management Plans to Continue as Going Concern Disclosure [Text Block]	NOTE 2 – MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN Basis of Presentation We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have incurred losses since inception and have an accumulated deficit of $ 46.2 To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance mipsagargin through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. Our cash and cash equivalents balance at June 30, 2016 was $ 0.9 85 In the event financing is not obtained, we may pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on: our business, results of operations, and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our auditors’ report issued in connection with our December 31, 2015 financial statements expressed an opinion that our capital resources as of the date of their audit report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Accordingly, our current cash level raises substantial doubt about our ability to continue as a going concern past September 2016. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

SUMMARY OF CRITICAL ACCOUNTING

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates. Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses. We incurred research and development expenses of approximately $ 0.3 0.6 0.6 1.4 Loss per Share Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of June 30, 2016 and 2015, as they would be anti-dilutive: Six months ended June 30, 2016 2015 Shares underlying options outstanding 5,615,123 8,926,695 Shares underlying warrants outstanding 40,088,993 18,549,724 Shares underlying convertible preferred stock outstanding 12,354,167 – Shares underlying convertible notes outstanding – 274,713 58,058,283 27,751,132 Derivative Liability The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding preferred stock. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date wherein instruments with the earliest issuance date would be settled first. The sequencing policy also considers contingently issuable additional shares, such as those issuable upon a stock split, to have an issuance date to coincide with the event giving rise to the additional shares. Using this sequencing policy, all instruments convertible into common stock, including warrants and the conversion feature of notes payable, issued subsequent to December 25, 2015 are classified as derivative liabilities. The Company values these derivative liabilities using the Black-Scholes option pricing model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations. Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. The derivative liability consists of our convertible preferred stock with anti-dilution provisions, and related warrants. The Company uses the Black-Scholes option pricing model to value its derivative liability which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life. Fair Value Measurements Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3: Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company has recorded a derivative liability for convertible preferred stock with anti-dilution provisions, and related warrants, as of June 30, 2016. The table below summarizes the fair values of our financial liabilities as of June 30, 2016 (in thousands): Fair Value at Fair Value Measurement Using June 30, Level 1 Level 2 Level 3 Derivative liability $ 422 $ — $ — $ 422 The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands): June 30, 2016 Balance at beginning of year $ 1,177 Additions to derivative instruments – Gain on change in fair value of derivative liability (755) Balance at end of year $ 422 Stock-Based Compensation We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation grant/award and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (FASB) issued FASB Accounting Standards Update (ASU) 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. The amendments in this update simplify several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently evaluating the effect that the adoption of this standard will have on our financial statements. In February 2016, the FASB issued FASB ASU 2016-02, “Leases (Topic 842)”. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For operating leases, a lessee would be required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the effect that the adoption of this ASU will have on our financial statements. In August 2014, the FASB issued Accounting Standards Update ASU 2014-15 “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments contained in this update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting. There are various other recently issued updates, most of which represented technical corrections to the accounting literature or application to specific industries, and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	6 Months Ended
	Jun. 30, 2016
Supplemental Cash Flow Information [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION There was no cash paid for interest and income taxes for the six months ended June 30, 2016 and 2015.

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 – ACCRUED EXPENSES Accrued expenses consist of the following (in thousands): June 30, 2016 December 31, 2015 Accrued compensation and benefits $ 2,317 $ 2,134 Accrued research and development 155 152 Accrued other 211 146 Total accrued expenses $ 2,683 $ 2,432

DERIVATIVE LIABILITY

DERIVATIVE LIABILITY	6 Months Ended
	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 6 – DERIVATIVE LIABILITY We account for equity-linked financial instruments, such as our convertible preferred stock, and our common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the respective agreement. Equity-linked financial instruments are accounted for as derivative liabilities, in accordance with ASC Topic 815 – Derivatives and Hedging, if the instrument allows for cash settlement or provide for modification of the exercise price in the event subsequent sales of our common stock are at a lower price per share than the then-current warrant exercise price. Additionally, financial instruments are classified as derivative liabilities if, as a result of the anti-dilution protection, there is no limit on the number of shares that may be subsequently issued and we conclude there are not adequate authorized shares available to provide for subsequent issuances. We classify derivative liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant. In December 2015, we issued shares of convertible preferred stock which contain anti-dilution protection for subsequent equity sales which occur within 18 months, and related warrants. As a result, the Company assessed its outstanding equity-linked financial instruments and concluded that this series of preferred stock, and related warrants, is subject to derivative accounting. The fair value of these shares are classified as a liability in the financial statements, with the change in fair value during the periods presented recorded in the statement of operations. During the six months ended June 30, 2016, we recorded a gain of $ 0.8 2016 Volatility 68 % Expected term (years) 12 months Risk-free interest rate 0.48 % Dividend yield None As of June 30, 2016, the derivative liability recognized in the financial statements was approximately $ 0.4

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 7 – COMMITMENTS AND CONTINGENCIES On March 16, 2016, Dr. Craig Dionne provided us his notice of termination as the company’s Chief Executive Officer and Chief Financial Officer. Dr. Dionne’s notice of termination alleges that such termination was for “Good Reason” as a result of a purported material change in his authority, functions, duties and responsibilities as chief executive officer. In the event that termination was for “Good Reason”, Dr. Dionne would be entitled to certain severance payments as well as other benefits. His notice of termination, in addition to requesting such severance, also requests the payment of Dr. Dionne’s annual and long term bonus for 2014 and 2015. On April 11, 2016, we received a letter from Dr. Dionne demanding approximately $ 2.3 The Company vigorously disputes that the termination of his employment was for “Good Reason,” as that term is defined in his employment agreement and under applicable law. This matter is at the early stages. While no litigation is pending at this time, there can be no assurance that this matter will be resolved in such a manner as to avoid litigation. Accordingly, the Company is unable at this time to predict the outcome of this matter, and any views formed as to the viability of these claims or the costs to the Company which could result may change from time to time as the matter proceeds through its course.

CAPITAL STOCK AND STOCKHOLDER'S

CAPITAL STOCK AND STOCKHOLDER'S EQUITY	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – CAPITAL STOCK AND STOCKHOLDER’S EQUITY Common Stock In September 2015, our board of directors approved amending our certificate of incorporation to effect a reverse stock split, subject to shareholder approval, at a ratio of not less than one-for-two (1 for 2), and not more than one-for thirty (1 for 30). On November 15, 2015, our shareholders approved the reverse stock split. As of June 30, 2016, the Company had not determined the degree, if any, of a potential reverse stock split. During the six months ended June 30, 2016, no warrants were exercised into common shares. During the six months ended June 30, 2015, 337,169 287,000

STOCK OPTIONS

STOCK OPTIONS	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 9 – STOCK OPTIONS Our 2009 Executive Compensation Plan (“2009 Plan”) and our 2007 Equity Compensation Plan (“2007 Plan”) each allow for the issuance of up to 6,000,000 12,000,000 Six months ended June 30, 2016 2015 Research and development $ 10 $ 22 General and administrative 28 50 $ 38 $ 72 Number of Weighted- Weighted-average Aggregate Outstanding at December 31, 2015 8,764,195 $ 1.60 Granted 411,000 $ 0.15 Expired (144,000) $ 1.87 Forfeited (3,416,072) $ 1.76 Outstanding at June 30, 2016 5,615,123 $ 1.39 2.9 $ — Exercisable at June 30, 2016 5,359,123 $ 1.44 2.9 $ — As of June 30, 2016, there was approximately $ 30,000 During the six months ended June 30, 2016, we issued options to purchase 106,000 305,000 106,000 212,600 0.07 0.33 Six months ended June 30, 2016 2015 Volatility 76.3 % 57.7 % Expected term (years) 2.8 3.5 Risk-free interest rate 1.1 % 1.0 % Dividend yield 0 % 0 %

WARRANTS

WARRANTS	6 Months Ended
	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 10 – WARRANTS In December 2015, in connection with a private placement of our securities, we issued an aggregate of 20,485,362 19,497,028 988,334 0.30 Number of Weighted- Weighted-average Aggregate Outstanding at December 31, 2015 42,277,445 $ 0.79 Forfeited (2,188,452) $ 3.24 Outstanding at June 30, 2016 40,088,993 $ 0.66 2.4 $ — Exercisable at June 30, 2016 40,088,993 $ 0.66 2.4 $ — During the six months ended June 30, 2016, no warrants were exercised. During the six months ended June 30, 2015, 337,169 287,000 Number of Weighted- Expiration Issued to consultants 841,000 $ 1.36 August 2016 through November 2020 Issued pursuant to 2012 financings 296,366 $ 3.00 December 2017 Issued pursuant to 2013 financings 4,376,228 $ 1.97 December 2017 through August 2018 Issued pursuant to 2014 financings 10,882,678 $ 0.82 December 2016 through June 2019 Issued pursuant to 2014 financings 23,692,721 $ 0.29 January 2017 through December 2020 40,088,993 During the six months ended June 30, 2016, no warrants were issued to consultants. During the six months ended June 30, 2015, we issued warrants to consultants to purchase 225,000 0.65 0.30 Total stock-based compensation expense of approximately $ 0 67,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 11 – SUBSEQUENT EVENTS On July 17, 2016, our board of directors adopted the GenSpera, Inc. Inducement Award Stock Option Plan. The plan is to be used in connection with the recruiting and inducement of senior management and employees. We did not seek approval of the plan by our stockholders. Pursuant to the plan, we may grant stock options for up to a total of 9,000,000 Effective August 1, 2016, the Company initiated its corporate reorganization plan by changing its name from GenSpera, Inc. to Inspyr Therapeutics, Inc. and changing its ticker symbol from GNSZ to NSPX. On August 2, 2016, and August 8, 2016, respectively, we entered into employment agreements with Christopher Lowe and Ronald Shazer to serve as our chief executive officer and chief medical officer, respectively. In conjunction with the employment agreement of Christopher Lowe, we issued Mr. Lowe 2,164,661 7 0.145 974,097 7

SUMMARY OF CRITICAL ACCOUNTIN18

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses. We incurred research and development expenses of approximately $ 0.3 0.6 0.6 1.4
Earnings Per Share, Policy [Policy Text Block]	Loss per Share Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of June 30, 2016 and 2015, as they would be anti-dilutive: Six months ended June 30, 2016 2015 Shares underlying options outstanding 5,615,123 8,926,695 Shares underlying warrants outstanding 40,088,993 18,549,724 Shares underlying convertible preferred stock outstanding 12,354,167 – Shares underlying convertible notes outstanding – 274,713 58,058,283 27,751,132
Derivatives, Policy [Policy Text Block]	Derivative Liability The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding preferred stock. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date wherein instruments with the earliest issuance date would be settled first. The sequencing policy also considers contingently issuable additional shares, such as those issuable upon a stock split, to have an issuance date to coincide with the event giving rise to the additional shares. Using this sequencing policy, all instruments convertible into common stock, including warrants and the conversion feature of notes payable, issued subsequent to December 25, 2015 are classified as derivative liabilities. The Company values these derivative liabilities using the Black-Scholes option pricing model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. The derivative liability consists of our convertible preferred stock with anti-dilution provisions, and related warrants. The Company uses the Black-Scholes option pricing model to value its derivative liability which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3: Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company has recorded a derivative liability for convertible preferred stock with anti-dilution provisions, and related warrants, as of June 30, 2016. The table below summarizes the fair values of our financial liabilities as of June 30, 2016 (in thousands): Fair Value at Fair Value Measurement Using June 30, Level 1 Level 2 Level 3 Derivative liability $ 422 $ — $ — $ 422 The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands): June 30, 2016 Balance at beginning of year $ 1,177 Additions to derivative instruments – Gain on change in fair value of derivative liability (755) Balance at end of year $ 422
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation grant/award and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (FASB) issued FASB Accounting Standards Update (ASU) 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. The amendments in this update simplify several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently evaluating the effect that the adoption of this standard will have on our financial statements. In February 2016, the FASB issued FASB ASU 2016-02, “Leases (Topic 842)”. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For operating leases, a lessee would be required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the effect that the adoption of this ASU will have on our financial statements. In August 2014, the FASB issued Accounting Standards Update ASU 2014-15 “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments contained in this update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting. There are various other recently issued updates, most of which represented technical corrections to the accounting literature or application to specific industries, and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

SUMMARY OF CRITICAL ACCOUNTIN19

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of June 30, 2016 and 2015, as they would be anti-dilutive: Six months ended June 30, 2016 2015 Shares underlying options outstanding 5,615,123 8,926,695 Shares underlying warrants outstanding 40,088,993 18,549,724 Shares underlying convertible preferred stock outstanding 12,354,167 – Shares underlying convertible notes outstanding – 274,713 58,058,283 27,751,132
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	The table below summarizes the fair values of our financial liabilities as of June 30, 2016 (in thousands): Fair Value at Fair Value Measurement Using June 30, Level 1 Level 2 Level 3 Derivative liability $ 422 $ — $ — $ 422
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block]	The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands): June 30, 2016 Balance at beginning of year $ 1,177 Additions to derivative instruments – Gain on change in fair value of derivative liability (755) Balance at end of year $ 422

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following (in thousands): June 30, 2016 December 31, 2015 Accrued compensation and benefits $ 2,317 $ 2,134 Accrued research and development 155 152 Accrued other 211 146 Total accrued expenses $ 2,683 $ 2,432

DERIVATIVE LIABILITY (Tables)

DERIVATIVE LIABILITY (Tables)	6 Months Ended
	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The significant assumptions used in the Black Scholes valuation of the derivative are as follows: 2016 Volatility 68 % Expected term (years) 12 months Risk-free interest rate 0.48 % Dividend yield None

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of operations for the six months ended June 30, 2016 and 2015 was as follows: Six months ended June 30, 2016 2015 Research and development $ 10 $ 22 General and administrative 28 50 $ 38 $ 72
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity under the Plans: Number of Weighted- Weighted-average Aggregate Outstanding at December 31, 2015 8,764,195 $ 1.60 Granted 411,000 $ 0.15 Expired (144,000) $ 1.87 Forfeited (3,416,072) $ 1.76 Outstanding at June 30, 2016 5,615,123 $ 1.39 2.9 $ — Exercisable at June 30, 2016 5,359,123 $ 1.44 2.9 $ —
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the six months ended June 30, 2016 and 2015: Six months ended June 30, 2016 2015 Volatility 76.3 % 57.7 % Expected term (years) 2.8 3.5 Risk-free interest rate 1.1 % 1.0 % Dividend yield 0 % 0 %

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Share-based Compensation, Activity [Table Text Block]	Transactions involving our equity-classified warrants are summarized as follows: Number of Weighted- Weighted-average Aggregate Outstanding at December 31, 2015 42,277,445 $ 0.79 Forfeited (2,188,452) $ 3.24 Outstanding at June 30, 2016 40,088,993 $ 0.66 2.4 $ — Exercisable at June 30, 2016 40,088,993 $ 0.66 2.4 $ —
Schedule of Outstanding Warrants to Purchase Common Stock [Table Text Block]	The following table summarizes outstanding common stock purchase warrants as of June 30, 2016: Number of Weighted- Expiration Issued to consultants 841,000 $ 1.36 August 2016 through November 2020 Issued pursuant to 2012 financings 296,366 $ 3.00 December 2017 Issued pursuant to 2013 financings 4,376,228 $ 1.97 December 2017 through August 2018 Issued pursuant to 2014 financings 10,882,678 $ 0.82 December 2016 through June 2019 Issued pursuant to 2014 financings 23,692,721 $ 0.29 January 2017 through December 2020 40,088,993

MANAGEMENT'S PLANS TO CONTINU24

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Management Plan [Line Items]
Deficit accumulated during the development stage	$ (46,245)	$ (45,265)
Cash and Cash Equivalents, at Carrying Value	$ 926	$ 2,465	$ 121	$ 2,316
Percentage of Cash and Cash Equivalents in Total Assets	85.00%

SUMMARY OF CRITICAL ACCOUNTIN25

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	58,058,283	27,751,132
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	0	274,713
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	12,354,167	0
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	40,088,993	18,549,724
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	5,615,123	8,926,695

SUMMARY OF CRITICAL ACCOUNTIN26

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1) $ in Thousands	Jun. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 422
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 422

SUMMARY OF CRITICAL ACCOUNTIN27

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning of year	$ 1,177
Additions to derivative instruments	0
Gain on change in fair value of derivative liability	(755)
Balance at end of year	$ 422

SUMMARY OF CRITICAL ACCOUNTIN28

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Summary Of Critical Accounting Policies [Line Items]
Research and Development Expense, Total	$ 323	$ 610	$ 646	$ 1,425

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Accrued Expenses [Line Items]
Accrued compensation and benefits	$ 2,317	$ 2,134
Accrued research and development	155	152
Accrued other	211	146
Total accrued expenses	$ 2,683	$ 2,432

DERIVATIVE LIABILITY (Details)

DERIVATIVE LIABILITY (Details)	6 Months Ended
	Jun. 30, 2016
Volatility	68.00%
Expected term (years)	12 months
Risk-free interest rate	0.48%
Dividend yield	0.00%

DERIVATIVE LIABILITY (Details T

DERIVATIVE LIABILITY (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Derivative, Gain on Derivative	$ 800
Derivative Liability	$ 422

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Textual) $ in Millions	Apr. 11, 2016USD ($)
Commitments And Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 2.3

CAPITAL STOCK AND STOCKHOLDER33

CAPITAL STOCK AND STOCKHOLDER'S EQUITY (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Class of Stock [Line Items]
Number of Warrants Exercised		337,169
Proceeds from Warrant Exercises	$ 0	$ 287
Common Stock [Member]
Class of Stock [Line Items]
Number of Warrants Exercised		337,169

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 38	$ 72
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	10	22
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 28	$ 50

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding at beginning of period (in shares) | shares	8,764,195
Number of shares, Granted (in shares) | shares	411,000
Number of shares, Expired (in shares) | shares	(144,000)
Number of shares, Forfeited (in shares) | shares	(3,416,072)
Number of shares, Outstanding at end of period (in shares) | shares	5,615,123
Number of shares, Exercisable (in shares) | shares	5,359,123
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share) | $ / shares	$ 1.6
Weighted-average exercise price, Granted (in dollars per share) | $ / shares	0.15
Weighted-average exercise price, Expired (in dollars per share) | $ / shares	1.87
Weighted-average exercise price, Forfeited (in dollars per share) | $ / shares	1.76
Weighted-average exercise price, Outstanding at end of period (in dollars per share) | $ / shares	1.39
Weighted-average exercise price, Exercisable (in dollars per share) | $ / shares	$ 1.44
Weighted-average remaining contractual term, Outstanding	2 years 10 months 24 days
Weighted-average remaining contractual term, Exercisable	2 years 10 months 24 days
Aggregate intrinsic value, Outstanding (in dollars) | $	$ 0
Aggregate intrinsic value, Exercisable (in dollars) | $	$ 0

STOCK OPTIONS (Details 2)

STOCK OPTIONS (Details 2) - Employee Stock Option [Member]	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	76.30%	57.70%
Expected term (years)	2 years 9 months 18 days	3 years 6 months
Risk-free interest rate	1.10%	1.00%
Dividend yield	0.00%	0.00%

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$ 30,000
Share Based Compensation Arrangement Options Issued To Non Employee Directors	106,000	106,000
Share Based Compensation Arrangement Options Issued To Consultants	305,000	212,600
Share Based Compensation Arrangement Options Issued To Consultants Weighted Average Price	$ 0.07	$ 0.33
Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	6,000,000
Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	12,000,000

WARRANTS (Details)

WARRANTS (Details) - Warrant [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding at beginning of period (in shares) | shares	42,277,445
Number of shares, Forfeited (in shares) | shares	(2,188,452)
Number of shares, Outstanding at ending of period (in shares) | shares	40,088,993
Number of shares, Exercisable (in shares) | shares	40,088,993
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share) | $ / shares	$ 0.79
Weighted-average exercise price, Forfeited (in dollars per share) | $ / shares	3.24
Weighted-average exercise price, Outstanding at end of period (in dollars per share) | $ / shares	0.66
Weighted-average exercise price, Exercisable (in dollars per share) | $ / shares	$ 0.66
Weighted-average remaining contractual term, Outstanding	2 years 4 months 24 days
Weighted-average remaining contractual term, Exercisable	2 years 4 months 24 days
Aggregate intrinsic value, Outstanding (in dollars) | $	$ 0
Aggregate intrinsic value, Exercisable (in dollars) | $	$ 0

WARRANTS (Details 1)

WARRANTS (Details 1) - Equity Classified Warrants [Member]	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Equity-classified warrants [Abstract]
Number of shares (in shares)	40,088,993
Consultant [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	841,000
Weighted Average Exercise price (in dollars per share) | $ / shares	$ 1.36
Investment Warrants Expiration Date Range Start	Aug. 31, 2016
Investment Warrants Expiration Date Range End	Nov. 30, 2020
Financing 2012 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	296,366
Weighted Average Exercise price (in dollars per share) | $ / shares	$ 3
Investment Warrants Expiration Date	Dec. 30, 2017
Financing 2013 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	4,376,228
Weighted Average Exercise price (in dollars per share) | $ / shares	$ 1.97
Investment Warrants Expiration Date Range Start	Dec. 30, 2017
Investment Warrants Expiration Date Range End	Aug. 30, 2018
Financing 2014 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	10,882,678
Weighted Average Exercise price (in dollars per share) | $ / shares	$ 0.82
Investment Warrants Expiration Date Range Start	Dec. 30, 2016
Investment Warrants Expiration Date Range End	Jun. 30, 2019
Financing 2014 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	23,692,721
Weighted Average Exercise price (in dollars per share) | $ / shares	$ 0.29
Investment Warrants Expiration Date Range Start	Jan. 31, 2017
Investment Warrants Expiration Date Range End	Dec. 31, 2020

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Warrants And Derivative Warrant Liability [Line Items]
Warrants Exercised		337,169
Proceeds from Warrant Exercises	$ 0	$ 287,000
Share-based Compensation, Total	38,000	$ 165,000
Warrant [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.65
Share-based Compensation, Total	$ 0	$ 67,000
Business And Advisory Services [Member]
Warrants And Derivative Warrant Liability [Line Items]
Warrants Issued to Consultants, Shares		225,000
Consultants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues			20,485,362
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.30
Placement Agent [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues			988,334
Investor [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues			19,497,028
Equity Classified Warrants [Member] | Minimum [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.30

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - Subsequent Event [Member] - $ / shares	Aug. 08, 2016	Aug. 02, 2016	Jul. 17, 2016
GenSpera, Inc. Inducement Award Stock Option Plan [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			9,000,000
Chief Executive Officer [Member] | Employee Stock Option [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Shares Issued		2,164,661
Deferred Compensation Arrangement with Individual, Maximum Contractual Term		7 years
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.145
Chief Medical Officer [Member] | Employee Stock Option [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Shares Issued	974,097
Deferred Compensation Arrangement with Individual, Maximum Contractual Term	7 years
Deferred Compensation Arrangement with Individual, Exercise Price	$ 0.15